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The tumor suppressor p53 normally acts as a brake to halt damaged cells from perpe-
trating their genetic errors into future generations. If p53 is disrupted by mutation, it may 
not only lose these corrective powers, but counterproductively acquire new capacities 
that drive cancer. A newly emerging manner in which mutant p53 executes its cancer 
promoting functions is by harnessing key proteins, which normally partner with its wild 
type, tumor-inhibiting counterpart. In association with the subverted activities of these 
protein partners, mutant p53 is empowered to act across multiple fundamental cellular 
pathways (regulating cell division and metabolism) and corrupt them to become cancer 
promoting.
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iNTRODUCTiON
Reliance on the tumor suppressive capacity of p53 is profoundly emphasized by its near universal 
malfunction in all cancers. P53 is the most altered gene in cancer. More than 50% of human cancers 
are afflicted with a p53 mutation. Severe consequences of p53 mutation include the failure to protect 
against cancer stimuli, compounded by the acquisition of new cancer promoting, “neomorphic” 
properties, referred to as “Gain of function” (GOF), covered by other reviews in this series [reviewed 
in Ref. (1)].
A particularly sinister GOF constitutes the subversion by mutant p53, of molecular partners of 
wild type (wt) p53, and this strategy forms the focus of this review. Specifically, mutant p53 conscripts 
proteins that normally partner with wt p53. This new association divests them of their anticancer 
activities and in place, they are corrupted to act as promoters of tumorigenesis [e.g., Ref. (2)]. A 
number of fundamental cellular functions that are normally tumor suppressive under the directive 
of wt p53 become severely derailed under the influence of mutant p53 to promote cancer. Mutant 
p53 deregulates normally tightly controlled fundamental processes (including control of the mitotic 
cell cycle, glycolysis, nucleic acid, and lipid synthesis) to promote deregulated, proliferative cancer 
cell growth (Figure 1). Identifying the nature and the regulation of this mutant p53, GOF predicts 
therapeutic avenues for reining-in the impact of mutant p53 and fighting cancer.
FiGURe 1 | wt p53 is induced to accumulate in response to stress to regulate fundamental cellular processes that protect against tumorigenesis. If 
p53 becomes mutated, it not only loses these tumor-protecting capacities but also may gain new functions through coercion of partner molecular partners normally 
engaged by wt p53.
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SUBveRSiON OF CeLL CYCLe 
ReGULATiON
Promyelocytic Leukemia
Proper cell cycle regulation is vital for normal cell function. 
Equally critical is the capacity to sense DNA damage and to inter-
rupt the cycle to instigate repair or eliminate cells with irreparable 
damage, as appropriate. Wt p53 is a key dictator of cellular fate 
in response to DNA damage resulting from cellular stresses. 
Partnership with the tumor suppressor promyelocytic leukemia 
(PML) protein facilitates p53 stress responses. Specifically, wt 
p53 stabilization and activation in response to stress is promoted 
by PML, through temporal co-recruitment of post-translational 
modifiers of p53 [kinases: CK1 (3), CK2 (4), HIPK2 (5); acetylases: 
CBP/p300 (6); MOZ (7)], to functional service depots, known 
as “PML nuclear bodies” (PML-NBs). PML-NBs facilitate the 
addition of post-translational modifications to p53, which relieve 
it from its normally labile state. Stabilized wt p53 accumulates, 
halts cell cycle progression, and initiates molecular responses 
to either repair DNA or direct the execution of incurable cells. 
PML in turn is a direct target of wt p53 transcriptional activation, 
which defines a positive regulatory loop (8). Further, PML-NBs 
associate with sites of active transcription and appear to facilitate 
gene expression (9). PML loss alone does not cause cancer [at 
least in mice (10)]; however, interference with its function may 
promote cancer, as consistent with its discovery in acute PML, 
where PML is fused with RAR-alpha to generate the oncogenic 
PML–RAR-alpha (11).
Significantly, mutant p53 enslavement of PML defines a para-
digm for mutant p53 disruption of tumor suppressive partners of 
wt p53. We identified that when p53 is mutated in cancer cells, its 
association with PML is constitutive, unlike the transient associa-
tion with its wt p53 counterpart in response to stress. Importantly, 
PML facilitates mutant p53 to aberrantly transcribe targets in the 
context of hijacked transcription factor NF-Y [(2), building on 
foundational NF-Y studies (12)].
More explicitly, wt p53 is a transcription factor that regulates 
its target genes (to control DNA repair, growth, and metabolic 
cascades), through direct engagement of its responsive elements. 
In stark contrast, mutant p53 is unable to directly engage these 
specific elements, but rather anchors onto other transcription 
factors and interferes with their transcription [including NF-Y 
(12)]. One transcriptional target of mutant p53 in association 
with NF-Y and PML is CDC25C, which triggers entry into 
FiGURe 2 | wt p53 is a pivotal point of connection between the mitotic cell cycle and the circadian clock. P53 activation is promoted by its transcriptional 
target PML. Once activated, wt p53 intervenes in the cell cycle through expression of its target gene, the checkpoint inhibitor p21. Upon stimulation, wt p53 can 
also intervene to affect the circadian clock. In contrast, when p53 is mutated, its interaction with PML becomes constitutive. Cancer is exacerbated when Per is 
mutated on a background of p53 mutation.
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mitosis (counteracting wt p53 activated growth arrest). 
Consistently, mutant p53 cancer cells may become growth 
dependent on PML, to the point where PML depletion leads 
to growth inhibition (2). Paradoxically, the capacity of PML to 
promote wt p53 as a tumor suppressor in healthy cells redefines 
PML as “oncogenic” when associated with mutant p53 in cancer 
cells [review in Ref. (13)].
At a higher level, cell cycle control is coordinated by the 
Circadian clock (14), and wt p53 defines a unique point of con-
vergence between these two fundamental vital cellular regulatory 
systems. The Circadian clock is subject both to wt p53 (15) and 
PML (16) regulation and in turn regulates important cell cycle 
genes, including p21, independently of p53 (17) (Figure 2). While 
disruption of the diurnal periods of ~24  h appears insufficient 
alone to cause cancer, new findings suggest that it can exacerbate 
cancer progression [reviewed in Ref. (14)].
At a molecular level, the clock is comprised of at least nine 
interplaying proteins, and we will discuss only those pertinent 
to this review. The clock is positively activated in a cyclic fashion 
through the combined activities of the two transcription factors: 
CLOCK and BMAL1 (Figure 2). As heterodimers, they engage 
E-Box motifs in the promoters of their target genes and induce 
transcription. Important transcriptional target genes, Per and 
Cry, and their protein products relocate to the nucleus and nega-
tively regulate CLOCK and BMAL1: forming a negative feedback 
loop. To restart the cycle, a stimulus such as light (or pertinently 
to our discussion DNA damage) must prompt elimination of 
Per and Cry, which is mediated through proteolysis [reviewed 
in Ref. (18)].
Wt p53 controls the clock through negative regulation of 
Per2 expression (Figure  2). Mechanistically, wt p53 competes 
for a promoter region of Per2 normally occupied by activating 
CLOCK/BMAL1 (15). In normal healthy cells, p53 levels oscillate 
temporally and Per2 levels inversely correspond. In cells under-
going stress, wt p53 accumulation inhibits Per2 transcription. On 
a background of mutant p53, cancer is exacerbated by mutation 
of either the clock regulatory gene Per2 (19), or PML loss (20). 
The capacity of PML to function as an upstream regulator of Per2 
is consistent with a common regulatory pathway (16). In sum, 
interplaying regulatory loops between p53, PML, the circadian 
clock, and the cell cycle are emerging, and their disruption has 
been linked to cancer in mouse models (19, 20). Links to human 
cancers are also emerging, with the possibility of sleep hormone 
therapies being trialed [i.e., melatonin (21)].
Phosphatase and Tensin homolog
Phosphatase and Tensin homolog (PTEN) is also a vital cell cycle 
regulator that has achieved its reputation as a tumor suppressor in 
the context of wild type (wt) p53. Pten curbs cell cycle progression 
and cell survival by suppressing PI3K–AKT/PKB cell survival 
pathway (22). PTEN functions as a tumor suppressor by stabiliz-
ing p53 protein in an Mdm2-dependent and/or -independent 
mechanism. (23). PTEN also increases the transcriptional activity 
of wt p53 through physical interaction (24). Reciprocally, wt p53 
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increases the transcription of PTEN by binding to the promoter 
of PTEN (25) and forming a feedback loop. These mutual rela-
tionships between PTEN and p53 promote tumor suppression.
In the context of mutant p53, in a diametrically opposing func-
tion, Pten promotes tumor growth (24). PTEN, in a comparable 
manner to PML, becomes oncogenic in cells expressing mutant 
p53 (26). PTEN stabilizes mutant p53 protein by inhibiting 
Mdm2-mediated degradation, which results in the inhibition 
of cell death and also in enhancement of cell proliferation (24). 
Additionally, PTEN increases the transcriptional activity of the 
mutant p53/acetylase CBP/NF-Y complex. This complex acti-
vates the transcription of c-Myc and Bcl-XL, which promotes cell 
survival and proliferation (26).
Polo-Like kinase-2
Polo-like kinase-2 (PLK2) is also a wt p53 target that contributes 
to cell cycle control. PLK2 is transcriptionally induced by wt 
p53 in response to the stress of DNA damage (27). PLK2 in a wt 
p53 setting is tumor suppressive, as engagement of p53 response 
elements in the promoter of PLK2 induces cell cycle arrest at 
the G2 checkpoint. In contrast, in a mutant p53 context, PLK2 
functions as an oncogene. Distinct, indirect interaction between 
mutant p53 and PLK2, mediated through the conscription of 
the transcription factor NF-Y (to the CCAAT box promoter 
sequences), increases cell proliferation. A reinforcing feed back 
loop is created by PLK2 in turn phosphorylating mutant p53 on 
a site not phosphorylated on wt p53. Phosphorylated mutant p53 
interacts more efficiently with p300 and promotes transcriptional 
activities of cell cycle activators (28). This feedback loop involving 
PLK2 defines a prototype cycle of reinforcement of mutant p53 
GOF (29).
DiveRSiON OF FUNDAMeNTAL 
CeLLULAR PATHwAYS
Rapid cell proliferation inherent in cancer growth is utterly 
dependent on the ready supply of “molecular building blocks.” 
Recent studies have identified that fundamental metabolic pro-
cesses normally regulated by wt p53 are extensively disrupted by 
mutant p53 to facilitate the supply of these necessities.
Nucleotide Metabolism
RRM2b
Proper repair of DNA damage is orchestrated by wt p53, which 
not only temporally halts cell cycle progression to allow repair, 
but also actively facilitates the supply of constituents for the 
repair. Specifically, in response to DNA damage, wt p53 tran-
scriptionally activates the small subunit of the ribonucleotide 
reductase (RRM2b) in a temporary manner, to facilitate the 
catalytic conversion of ribonucleoside diphosphates to deoxyri-
bonucleoside diphosphates, which is an essential step for DNA 
synthesis. In contrast, when p53 is mutated, it constitutively 
upregulates RRM2b expression. Importantly, the mechanism of 
transcriptional activation of RRM2b is dependent on the status 
of p53: where wt p53 engages its REs in the intronic region and 
in contrast mutant p53 localizes to the promoter. Further, it has 
emerged that mutant p53 transcriptionally drives additional 
nucleotide metabolic genes, both in the salvage and new synthesis 
pathways, through co-recruitment with the transcription factor 
ETS2, to its target gene promoters. ETS2 engagement by mutant 
p53 is a recurring theme, as we discuss below for epigenetic regu-
lation. Overall, mutant p53 upregulates nucleotide biosynthesis, 
which contributes to meeting the voracious demands of rapidly 
proliferating and invading cancers (30).
Glucose Metabolism
Glucose Transporter 1
Regulated glucose metabolism is vital for maintaining healthy, 
normal cell homeostasis, in contrast to the voracious consump-
tion of glucose that feeds cancer cell proliferation and is inher-
ent in the “Warburg effect.” Proper glucose regulation is then 
an important tumor suppressive capacity of wt p53. Wt p53 
regulates glucose metabolism by restricting cellular glucose at 
three levels through (31): (1) suppression of the expression of 
glucose transporter 1 (GLUT1) and 4 (32); (2) transcriptional 
regulation of target genes, which inhibit glycolysis [TIGAR (33)] 
and gluconeogenesis in the liver (34); and (3) direct binding 
and inhibition of the rate-limiting enzyme (glucose-6-phophate 
dehydrogenase) in an alternative anabolic pathway [the pentose 
phosphate pathway (35)].
Profoundly, when p53 is mutated, not only are these points 
of regulating glucose metabolism lost but further glucose uptake 
is accentuated through a novel GOF. This disastrous mutant p53 
GOF is the shunting of the glucose transporter, Glut1, to the cell 
membrane surface where it stokes glucose uptake by cancer cells 
(36). Elevated glucose levels feed into metabolic anabolism to 
provide the increased demand for the molecular building blocks 
required to support rapid cancer cell proliferation, inherent in 
the Warburg effect. Reciprocally, glucose maintains mutant p53 
stability and promotes cancer cell growth (37), generating a posi-
tive regulatory loop.
Reliance on a mutant p53-dependent enhanced supply of 
glucose to foster cell proliferation defines a unique point of 
vulnerability in cancer cells. This appetite for glucose identifies 
a potential therapy target which is currently being extensively 
investigated [i.e., ketogenic diets (38) and repurposing of the 
widely used diabetic metformin (39)].
Lipid Metabolism
Sterol Regulatory Element-Binding Proteins
A controlled supply of lipids is vital for regulated cell division and 
maintenance. Nearly every enzyme in the fatty acid and choles-
terol synthesis are subject to regulation by the transcription factor 
of sterol regulatory element-binding proteins [SREBPs (40)]. 
Specifically, SREBP-1 dictates expression of lipogenic enzymes 
including fatty acid synthase, while SREBP-2 regulates cholesterol 
synthesis [reviewed in Ref. (41)]. In response to stress, consistent 
with halting cell division, wt p53 restrains lipid accumulation 
by inhibiting expression of the transcription factor SREBP-1, 
and in turn triglyceride synthesis, and lipogenic genes (41). In 
contrast, mutant p53 engages the SREBPs (both SREBP-1 and -2) 
directly. Mutant p53 is recruited to SREBP target gene promoters 
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(although co-recruitment remains to be directly demonstrated). 
Mutant p53 appears to upregulate transcription of key enzymes 
in the sterol pathway and fatty acid biosynthesis pathway. Mutant 
p53 correlates with increased expression of enzymes in both the 
mevalonate synthesis (cholesterol) pathway and fatty acid synthe-
sis pathways. Mutant p53 upregulation of these vital pathways is 
consistent with meeting increased demand for membrane lipids 
in rapidly proliferating cancer cells (42).
Antioxidant Pathways
Nuclear Factor Erythroid-Related Factor-2
Reactive oxygen intermediates perform important cellular func-
tions including signaling; however, they are seriously damaging 
to normal cells if not properly contained and are linked to cancer 
[review in Ref (43)]. A master redox regulator is the transcription 
factor, nuclear factor erythroid-related factor-2 (NRF2) (44). P53 
acts as a stress-rheostat controller of Nrf2 levels. Specifically, in 
response to mild stress, p53 transcriptionally activates the vital 
cell cycle inhibitor, p21, which binds to Nrf2 and consequently 
relieves it from its normal restraint (45). Relocation of NRF2 from 
the cytoplasm to the nucleus permits it to regulate multiple anti-
oxidant targets, where some ~200 genes have been reported (44). 
These include the NADH-quinone oxidoreductase1 (NQO1), 
which also has differential function in a wt (46) versus mutant 
p53 context (47) (but will not be further elaborated here). When 
stress insults are severe, however, p53 inhibits Nrf2 (45). This 
exquisite level of control is consistent with p53 instigating repair 
in response to mild stress insults while intervening to prevent 
remedial action in those that are irrevocably damaged.
A novel GOF of mutant p53 is its capacity to reduce Nrf2 
protein levels (without impacting its mRNA), in response to 
oxidative stress. The consequence is low levels of Nrf2 target 
detoxifying genes and elevated levels of reactive oxygen species 
(ROS). Remarkably, in contrast to growth inhibition imposed on 
wt p53 cells subject to oxidative stress, those with mutant p53 
tolerate elevated ROS, survive, and proliferate (48).
iNTeRFeReNCe wiTH 
TRANSCRiPTiONAL ReGULATiON
When p53 is mutated, a radical shift in transcriptional activity 
occurs, which is conducive to cancer promotion. An altered 
repertoire of transcription factor engagement is emerging for 
mutant p53. While mutant p53 is not able to directly engage wt 
p53 response elements, it may instead directly bind its wt coun-
terpart and impose a dominant negative effect over wt p53 func-
tions, including depriving it of capacity to regulate transcription. 
Mutant p53 may also engage transcription factors that wt p53 does 
not, including the family members p63 and p73 and disrupt their 
functions. More specifically, the presence of arginine at codon 
72 dictates the capacity of mutant p53 to sequester p73, where 
mutants with proline are incapable of this inactivation (49, 50).
Beyond this negative regulation of wt p53 and its family 
members, mutant p53 may hijack transcription factor partners 
and disrupt their normal transcriptional activity (as mentioned 
above). Mutant p53 has been reported to engage NF-Y, NF-kappa 
B, SP1, E2F1, ETS1, ETS2, and SREBP. The outcome may be 
altered target engagement, or a change in the rate of transcrip-
tion relative to a wt p53 context. These features of mutant p53 
have been comprehensively reviewed recently (51), so we will 
concentrate on new findings.
Swi/SNF
At a higher level, mutant p53 disruption of chromatin regula-
tion is also now emerging. In order for wt p53 to access specific 
DNA responsive elements in the regulatory regions (upstream 
promoters or introns) of its target genes, it must coordinate with 
numerous chromatin regulators to expose appropriate regulatory 
elements and associated DNA to be transcribed (52). Wt p53 
exercises this activity in the context of components of the ATP-
dependent nucleosomal remodeler SWI/SNF complex (53, 54). 
Mutant p53 has now also been identified to engage the SWI/SNF 
complex. However, in contrast to wt p53, mutant p53 is unable to 
directly engage wt p53 DNA response elements but rather local-
izes to distinct gene promoters through alternative transcription 
factors (as mentioned above). Through this co-recruitment, the 
SWI/SNF complex is predicted to facilitate more than 40% of all 
the genes transcribed by mutant p53 [where the primary example 
of altered regulation is the vascular endothelial growth factor 
receptor 2; VEGF2, which is vital for neoangiogenesis associated 
with oncogenesis (55)].
MLLs/MOZ
Mutant p53 can also alter transcriptional machinery, through dis-
tinct interactions from its wt counterpart. Wt p53 is able to physi-
cally interact through its core domain with the RNA polymerase 
II (POL II, large subunit) and limit target gene expression (56). 
In contrast, through engagement of the transcription factor ETS2 
[as first demonstrated in Ref. (57)], mutant p53 is able to redirect 
POLII to transcribe the histone methyl transferases MLL1 and 
MLL2 and also acetyltransferase MOZ (58). This emphasizes the 
insidious capacity of mutant p53 to overpower fundamental tran-
scriptional processes to support elevated proliferation. The newly 
emerging application of small molecule compounds to target 
chromatin regulators predicts application for cancers dependent 
on mutant p53. Specifically, cell growth inhibition of mutant p53 
cancer has been demonstrated with prototoype inhibitors (58).
CONCLUSiON
Corruption of the normal interactions between wt p53 and its 
molecular partners appears to lie at the heart of significant tumor 
promoting mutant p53 GOFs. Intriguingly, p53 mutations, which 
eliminate its function (e.g., deletion mutations), are rare, in con-
trast to the frequent activating missense mutations. To an extent, 
which appears unequaled by any other gene, mutation of p53 
confers an exceptionally wide range of fundamental new proper-
ties that promote deregulated cell growth. These findings provide 
new insights directing innovative and rational approaches to 
therapeutically targeting cancers with mutant p53, which have 
proven particularly resistant to treatment. The polarized func-
tions of these key p53 partners, would also caution that p53 status 
be an important criteria to consider prior to adoption of therapies 
directed toward these targets.
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